Locally Active PPAR Agonist Program

The program is aimed to develop a locally, in the gut, active PPAR agonist as a first-in-class treatment of IBD. The rationale is supported by clinical data. The compounds exhibit gastrointestinal anti-inflammatory effect avoiding systemic exposure. The program is in preclinical phase.

Albireo Homepage